Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (4 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
2 selected
)
Type
Guidance (33)
Quality standard (0)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (1)
Diagnostics guidance (1)
NICE guidelines (1)
Technology appraisal guidance (33)
Apply filters
Showing 1 to 25 of 33
Sort by
Date
Title
Apply sorting
multiple myeloma
Remove multiple myeloma filter
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Melphalan flufenamide with dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA968
25 April 2024
25 April 2024
Idecabtagene vicleucel for treating relapsed and refractory
multiple myeloma
after 3 or more treatments (terminated appraisal)
TA936
30 November 2023
30 November 2023
Daratumumab with lenalidomide and dexamethasone for untreated
multiple myeloma
when a stem cell transplant is unsuitable
TA917
25 October 2023
25 October 2023
Daratumumab with bortezomib and dexamethasone for previously treated
multiple myeloma
TA897
6 June 2023
6 June 2023
Ciltacabtagene autoleucel for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA889
17 May 2023
17 May 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory
multiple myeloma
TA870
22 February 2023
22 February 2023
Teclistamab for treating relapsed or refractory
multiple myeloma
after 3 or more therapies (terminated appraisal)
TA869
16 February 2023
16 February 2023
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA841
22 November 2022
22 November 2022
Daratumumab monotherapy for treating relapsed and refractory
multiple myeloma
TA783
13 April 2022
13 April 2022
Daratumumab with bortezomib, melphalan and prednisone for untreated
multiple myeloma
(terminated appraisal)
TA771
9 February 2022
9 February 2022
Daratumumab in combination for untreated
multiple myeloma
when a stem cell transplant is suitable
TA763
2 February 2022
2 February 2022
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA726
22 September 2021
22 September 2021
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA727
22 September 2021
22 September 2021
Selinexor with low-dose dexamethasone for treating refractory
multiple myeloma
(terminated appraisal)
TA700
19 May 2021
19 May 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated
multiple myeloma
TA695
28 April 2021
28 April 2021
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed
multiple myeloma
TA680
3 March 2021
3 March 2021
Carfilzomib for previously treated
multiple myeloma
TA657
18 November 2020
18 November 2020
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory
multiple myeloma
TA658
18 November 2020
18 November 2020
Daratumumab with lenalidomide and dexamethasone for untreated
multiple myeloma
(terminated appraisal)
TA634
30 June 2020
30 June 2020
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory
multiple myeloma
(terminated appraisal)
TA602
25 September 2019
25 September 2019
Lenalidomide with bortezomib and dexamethasone for untreated
multiple myeloma
(terminated appraisal)
TA603
25 September 2019
25 September 2019
Lenalidomide for the treatment of
multiple myeloma
in people who have received at least 2 prior therapies
TA171
18 June 2009
26 June 2019
Lenalidomide plus dexamethasone for
multiple myeloma
after 1 treatment with bortezomib
TA586
26 June 2019
26 June 2019
Lenalidomide plus dexamethasone for previously untreated
multiple myeloma
TA587
26 June 2019
26 June 2019
Denosumab for preventing skeletal-related events in
multiple myeloma
(terminated appraisal)
TA549
5 December 2018
5 December 2018
Current page
1
2
Page
1
of
2
Next page
Results per page
10
25
50
All
Back to top